The CHI Centers of Excellence (COE) Program

CHI Center of ExcellenceIn early 2024, CHI will launch a new application cycle in the CHI Center of Excellence (COE) program. This prestigious program recognizes expert centers that provide the highest level of multi-disciplinary care to congenital hyperinsulinism (HI) patients and their families and demonstrate an ongoing commitment to research and collaboration.

Centers interested in applying or reapplying for the designation can apply using this application link.

Application criteria and scoring information are available on the CHI website. All existing HI COE Centers will need to reapply to maintain the designation. Additionally, CHI is committed to supporting the growth of emerging HI centers globally and will provide constructive feedback on areas of applications that need improvement.  Centers can review the application criteria and scoring by reviewing the COE Application Rubric here.

History of the COE Program

Some superb institutions from around the world are known for providing excellent HI care and participating in groundbreaking research. Yet, until CHI created the COE program, no review process or certificate was awarded to institutions for the care of those with HI.

In June 2021, the first group of centers received the COE designation. This honor recognizes expert centers that provide the highest level of multi-disciplinary care to congenital hyperinsulinism patients and their families and an ongoing commitment to research and collaboration.

The CHI COE designation application was developed by an international committee of HI specialists, clinicians, and patient representatives who worked together to identify the requirements. The criteria include demonstrated excellence in clinical care, academic research, collaboration, and a commitment to patient care.

Hyperinsulinism centers from all over the world were invited to submit an application to receive the designation. The online application consisted of 33 questions that are associated with identified criteria to determine comprehensive and expert HI care.

The Inaugural CHI COEs named in 2021 were:

  • Congenital Hyperinsulinism Center at the Children’s Hospital of Philadelphia, PA, United States
  • The Hyperinsulinism Center at Cook Children’s Medical Center in Fort Worth, TX, United States
  • Great Ormond Street Hospital Congenital Hyperinsulinism Service in London, in the United Kingdom
  • Charite-Universitatsmedizin Berlin and the University Children’s Hospital Duesseldorf partnership in Germany
  • Collaborative Alliance on Congenital Hyperinsulinism headquartered in Magdeburg, Germany
  • Northern Congenital Hyperinsulinism Service in Manchester and Liverpool, in the United Kingdom

Read the full press release here.

Press release also available in German here.

If you have any questions, please contact Tai Pasquini, CHI Director of Research and Policy, by emailing tpasquini@congenitalhi.org or calling her at 973-842-7559.

The CHI COE Program was made possible through the Global Genes 2020 RARE Patient Impact Grant Program, the Chan Zuckerberg Initiative Rare As One Grant, and other generous donors.

Global Genes
Rare As One


Share